4.5 Article

Discovery of Natural Products Possessing Selective Eukaryotic Readthrough Activity: 3-epi-Deoxynegamycin and Its Leucine Adduct

Related references

Note: Only part of the references are listed.
News Item Biotechnology & Applied Microbiology

Doubts raised over 'read-through' Duchenne drug mechanism

Cormac Sheridan

NATURE BIOTECHNOLOGY (2013)

Article Chemistry, Medicinal

Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy

Akihiro Taguchi et al.

ACS MEDICINAL CHEMISTRY LETTERS (2012)

Article Chemistry, Organic

Total synthesis of (+)-negamycin and its 5-epi-derivative

Shigenobu Nishiguchi et al.

TETRAHEDRON (2010)

Article Immunology

Nonaminoglycoside compounds induce readthrough of nonsense mutations

Liutao Du et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Article Microbiology

Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit

Susan J. Schroeder et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)

Article Clinical Neurology

Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human

Marcella Neri et al.

NEUROMUSCULAR DISORDERS (2007)

Article Multidisciplinary Sciences

PTC124 targets genetic disorders caused by nonsense mutations

Ellen M. Welch et al.

NATURE (2007)

Article Biochemistry & Molecular Biology

Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice

M Arakawa et al.

JOURNAL OF BIOCHEMISTRY (2003)

Article Chemistry, Medicinal

N- and C-terminal modifications of negamycin

B Raju et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)